JP2013529647A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529647A5 JP2013529647A5 JP2013516840A JP2013516840A JP2013529647A5 JP 2013529647 A5 JP2013529647 A5 JP 2013529647A5 JP 2013516840 A JP2013516840 A JP 2013516840A JP 2013516840 A JP2013516840 A JP 2013516840A JP 2013529647 A5 JP2013529647 A5 JP 2013529647A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- disorder
- group
- composition
- nephritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 19
- 201000010099 disease Diseases 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 6
- 201000008383 nephritis Diseases 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 claims 1
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000034486 Multi-organ failure Diseases 0.000 claims 1
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 206010052568 Urticaria chronic Diseases 0.000 claims 1
- 206010053648 Vascular occlusion Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000024376 chronic urticaria Diseases 0.000 claims 1
- 208000002528 coronary thrombosis Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 208000021331 vascular occlusion disease Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/823,039 US20100311753A1 (en) | 2008-12-22 | 2010-06-24 | C5aR ANTAGONISTS |
| US12/823,039 | 2010-06-24 | ||
| US13/072,616 | 2011-03-25 | ||
| US13/072,616 US20110275639A1 (en) | 2008-12-22 | 2011-03-25 | C5aR ANTAGONISTS |
| PCT/US2011/041910 WO2011163640A1 (en) | 2010-06-24 | 2011-06-24 | C5ar antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016053725A Division JP6189989B2 (ja) | 2010-06-24 | 2016-03-17 | Ｃ５ａＲアンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013529647A JP2013529647A (ja) | 2013-07-22 |
| JP2013529647A5 true JP2013529647A5 (enExample) | 2014-08-14 |
Family
ID=47996916
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013516840A Withdrawn JP2013529647A (ja) | 2010-06-24 | 2011-06-24 | Ｃ５ａＲアンタゴニスト |
| JP2016053725A Active JP6189989B2 (ja) | 2010-06-24 | 2016-03-17 | Ｃ５ａＲアンタゴニスト |
| JP2017150928A Active JP6438086B2 (ja) | 2010-06-24 | 2017-08-03 | Ｃ５ａＲアンタゴニスト |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016053725A Active JP6189989B2 (ja) | 2010-06-24 | 2016-03-17 | Ｃ５ａＲアンタゴニスト |
| JP2017150928A Active JP6438086B2 (ja) | 2010-06-24 | 2017-08-03 | Ｃ５ａＲアンタゴニスト |
Country Status (14)
| Country | Link |
|---|---|
| US (7) | US9126939B2 (enExample) |
| EP (1) | EP2585064B1 (enExample) |
| JP (3) | JP2013529647A (enExample) |
| CN (1) | CN103068385B (enExample) |
| BR (1) | BR112012033075B1 (enExample) |
| DK (1) | DK2585064T3 (enExample) |
| ES (1) | ES2632975T3 (enExample) |
| HR (1) | HRP20171176T1 (enExample) |
| HU (1) | HUE033644T2 (enExample) |
| PL (1) | PL2585064T3 (enExample) |
| PT (1) | PT2585064T (enExample) |
| RS (1) | RS56332B1 (enExample) |
| SI (1) | SI2585064T1 (enExample) |
| WO (1) | WO2011163640A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202200074T1 (it) | 2008-12-22 | 2022-03-21 | Chemocentryx Inc | Antagonisti di c5ar |
| US20110275639A1 (en) * | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| HRP20171176T1 (hr) * | 2010-06-24 | 2017-10-06 | Chemocentryx, Inc. | C5ar antagonisti |
| SMT202400142T1 (it) | 2014-01-13 | 2024-05-14 | Aurigene Oncology Ltd | Enantiomeri (r) e (s) di n-(5-(3-idrossipirrolidin-1-il)-2-morfolinoossazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)ossazolo-carbossammide in qualità di inibitori di irak4 per il trattamento di un cancro |
| KR20170016500A (ko) * | 2014-06-20 | 2017-02-13 | 오리진 디스커버리 테크놀로지스 리미티드 | Irak4 저해제로서의 치환된 인다졸 화합물 |
| EP3682879B1 (en) * | 2014-09-29 | 2022-08-03 | ChemoCentryx, Inc. | Processes and intermediates in the preparation of c5ar antagonists |
| MX2022006069A (es) | 2016-01-14 | 2023-01-12 | Chemocentryx Inc | Metodo para tratar glomerulopatia c3. |
| WO2017176620A2 (en) * | 2016-04-04 | 2017-10-12 | Chemocentryx, Inc. | SOLUBLE C5aR ANTAGONISTS |
| CN120267671A (zh) | 2017-03-31 | 2025-07-08 | 奥锐金肿瘤有限公司 | 用于治疗血液病的化合物和组合物 |
| EP3978523A1 (en) | 2017-04-03 | 2022-04-06 | InflaRx GmbH | Treatment of inflammatory diseases with inhibitors of c5a activity |
| NZ759297A (en) | 2017-05-31 | 2026-03-27 | Chemocentryx Inc | 6-5 fused rings as c5a inhibitors |
| KR102586710B1 (ko) | 2017-05-31 | 2023-10-10 | 케모센트릭스, 인크. | C5a 억제제로서의 5-5 융합 고리 |
| CN111201241A (zh) * | 2017-06-23 | 2020-05-26 | 因弗拉克斯有限责任公司 | 用C5a活性抑制剂治疗炎性疾病 |
| CA3077395A1 (en) * | 2017-10-30 | 2019-05-09 | Chemocentryx, Inc. | Deuterated compounds as immunomodulators |
| US20190134020A1 (en) | 2017-10-31 | 2019-05-09 | Chemocentryx, Inc. | C5aR INHIBITOR REDUCTION OF URINARY sCD163 |
| MX2020003666A (es) | 2017-10-31 | 2020-08-03 | Curis Inc | Compuestos y composiciones para el tratamiento de trastornos hematologicos. |
| WO2019126424A1 (en) * | 2017-12-22 | 2019-06-27 | Chemocentryx, Inc. | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS |
| CN111788184B (zh) | 2017-12-22 | 2023-12-22 | 凯莫森特里克斯股份有限公司 | 用作C5aR抑制剂的二芳基取代的5,5-稠合环化合物 |
| PH12020500583B1 (en) * | 2018-01-10 | 2024-02-21 | Idorsia Pharmaceuticals Ltd | 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases |
| CN111683937A (zh) * | 2018-01-19 | 2020-09-18 | 爱杜西亚药品有限公司 | C5a受体调节剂 |
| ES2993034T3 (en) * | 2018-04-02 | 2024-12-20 | Chemocentryx Inc | Prodrugs of fused-bicyclic c5ar antagonists |
| CN108727354A (zh) * | 2018-05-16 | 2018-11-02 | 张玉叶 | 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用 |
| CN108440513A (zh) * | 2018-05-16 | 2018-08-24 | 张玉叶 | 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用 |
| CN108727355A (zh) * | 2018-05-16 | 2018-11-02 | 张玉叶 | 一种甲酰胺类衍生物、制备方法及其在抗肿瘤药物中的应用 |
| CN108440514A (zh) * | 2018-05-16 | 2018-08-24 | 张玉叶 | 一种甲酰胺类衍生物、制备方法及其在抗肿瘤药物中的应用 |
| CN108558844A (zh) * | 2018-05-16 | 2018-09-21 | 张玉叶 | 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用 |
| CA3102403A1 (en) | 2018-06-07 | 2019-12-12 | Chemocentryx, Inc. | Dosing and effect of c5a antagonist with anca-associated vasculitis |
| EP4487915A3 (en) * | 2018-11-30 | 2025-03-19 | ChemoCentryx, Inc. | Capsule formulations |
| US11872217B2 (en) | 2019-07-10 | 2024-01-16 | Chemocentryx, Inc. | Indanes as PD-L1 inhibitors |
| CR20220216A (es) | 2019-10-16 | 2023-01-09 | Chemocentryx Inc | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 |
| US11713307B2 (en) | 2019-10-16 | 2023-08-01 | Chemocentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases |
| KR20220098179A (ko) | 2019-11-08 | 2022-07-11 | 케모센트릭스, 인크. | 보체 성분 C5a 수용체의 유리 염기 결정질 형태 |
| MX2022005406A (es) | 2019-11-08 | 2022-05-24 | Chemocentryx Inc | Forma amorfa de un receptor de componente c5a de complemento. |
| CN118908883A (zh) * | 2019-11-08 | 2024-11-08 | 凯莫森特里克斯股份有限公司 | 补体成分c5a受体的盐形式 |
| BR112022019090A2 (pt) | 2020-03-27 | 2022-11-08 | Inflarx Gmbh | Inibidores de c5a para o tratamento de infecção por coronavírus |
| TW202208427A (zh) | 2020-05-06 | 2022-03-01 | 德商因夫萊亞斯有限公司 | 人源化抗ｃ５ａ抗體 |
| AU2021321901A1 (en) * | 2020-08-07 | 2023-03-09 | Kira Pharmaceuticals (Suzhou) Ltd. | Compounds as C5ar inhibitors |
| WO2022078269A1 (zh) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
| CN116529241A (zh) * | 2020-10-28 | 2023-08-01 | 坎莫森特里克斯公司 | 治疗化脓性汗腺炎的方法 |
| MX2023004801A (es) * | 2020-10-28 | 2023-05-10 | Chemocentryx Inc | Metodos de tratamiento de hidradenitis supurativa. |
| US12178821B2 (en) | 2021-04-08 | 2024-12-31 | Curis, Inc. | Combination therapies for the treatment of cancer |
| CN117402104A (zh) * | 2021-12-06 | 2024-01-16 | 重庆医科大学 | 阿伐可泮手性中间体的制备方法 |
| WO2023158722A2 (en) * | 2022-02-16 | 2023-08-24 | Teva Pharmaceuticals International Gmbh | Processes for preparation of avacopan and intermediates thereof |
| US12180274B2 (en) | 2023-05-26 | 2024-12-31 | Inflarx Gmbh | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity |
| WO2025037010A1 (en) * | 2023-08-16 | 2025-02-20 | Inflarx Gmbh | Fused piperidinyl bicyclic and related compounds for use in the treatment of diseases |
| WO2025227089A1 (en) | 2024-04-26 | 2025-10-30 | Amgen Inc. | Solid state forms of (2r,3s)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-n-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide |
| US20260027049A1 (en) | 2024-07-23 | 2026-01-29 | Amgen Inc. | Avacopan formulations |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4686100A (en) | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
| WO1999065867A1 (en) * | 1998-06-17 | 1999-12-23 | Du Pont Pharmaceuticals Company | Cyclic hydroxamic acids as metalloproteinase inhibitors |
| AU772477B2 (en) | 1998-08-28 | 2004-04-29 | Scios Inc. | Inhibitors of p38-alpha kinase |
| US6713502B2 (en) | 2000-05-05 | 2004-03-30 | Smithkline Beecham Corporation | Anti-infectives |
| CN1231464C (zh) | 2000-08-10 | 2005-12-14 | 三菱制药株式会社 | 新型3－取代的脲衍生物及其药学应用 |
| AU2001290873B2 (en) * | 2000-09-11 | 2006-07-27 | Sepracor Inc. | Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| US7294637B2 (en) * | 2000-09-11 | 2007-11-13 | Sepracor, Inc. | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter |
| WO2002022556A1 (en) | 2000-09-14 | 2002-03-21 | Mitsubishi Pharma Corporation | Novel amide derivatives and medicinal use thereof ugs |
| DE60039921D1 (de) | 2000-09-29 | 2008-09-25 | Neurogen Corp | Hochaffine kleinmolekülige c5a-rezeptor-modulatoren |
| SE524438C2 (sv) | 2000-10-05 | 2004-08-10 | Magnus Georg Goertz | Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium |
| WO2003008824A1 (de) | 2001-07-19 | 2003-01-30 | Luk Lamellen Und Kupplungsbau Beteiligungs Kg | Ausrücksystem zur betätigung einer kupplung eines fahrzeuges |
| CA2457461C (en) | 2001-08-17 | 2013-12-24 | Tanox, Inc. | Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b |
| US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| AU2003225971A1 (en) | 2002-03-28 | 2003-10-13 | Yang Gao | Substituted biaryl amides as c5a receptor modulators |
| JP2005530719A (ja) | 2002-03-29 | 2005-10-13 | ニューロジェン コーポレーション | 病原性炎症要素を有する状態の治療のための組み合わせ療法 |
| US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| US7169775B2 (en) | 2002-08-21 | 2007-01-30 | Neurogen Corporation | Amino methyl imidazoles as C5a receptor modulators |
| US7455837B2 (en) | 2002-11-05 | 2008-11-25 | The Regents Of The University Of Michigan | Compositions and methods for the diagnosis and treatment of sepsis |
| FR2846654A1 (fr) | 2002-11-05 | 2004-05-07 | Servier Lab | Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| ATE552253T1 (de) | 2002-11-08 | 2012-04-15 | Novartis Int Pharm Ltd | 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren |
| AU2003902354A0 (en) | 2003-05-15 | 2003-05-29 | Harkin, Denis W. | Treatment of haemorrhagic shock |
| WO2005007087A2 (en) | 2003-07-03 | 2005-01-27 | Neurogen Corporation | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| EA200700117A1 (ru) | 2004-06-24 | 2007-06-29 | Инсайт Корпорейшн | N-замещенные пиперидины и их применение в качестве фармацевтических препаратов |
| US7635698B2 (en) | 2004-12-29 | 2009-12-22 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| NZ561613A (en) | 2005-02-18 | 2010-12-24 | Astrazeneca Ab | Antibacterial piperidine derivatives |
| WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US20070112015A1 (en) * | 2005-10-28 | 2007-05-17 | Chemocentryx, Inc. | Substituted dihydropyridines and methods of use |
| RS55192B1 (sr) | 2005-11-24 | 2017-01-31 | Dompé Farm S P A | Derivati (r)-arilkilamina i farmaceutske kompozicije koje ih sadrže |
| WO2008022060A2 (en) | 2006-08-14 | 2008-02-21 | Novartis Ag | Imidazo-pyridine derivatives for modulating protein kinase activity |
| EP2077842A2 (en) | 2006-10-31 | 2009-07-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of an egfr antagonist for the treatment of glomerolonephritis |
| US20100190824A1 (en) | 2007-06-29 | 2010-07-29 | Prabhat Kumar | Novel Substituted Piperidones as HSP Inducers |
| AU2009282480B2 (en) | 2008-08-11 | 2015-05-07 | Children's Medical Center Corporation | Halofuginone analogs for inhibition of tRNA synthetases and uses thereof |
| WO2010025510A1 (en) | 2008-09-03 | 2010-03-11 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
| US20100074863A1 (en) | 2008-09-17 | 2010-03-25 | Yat Sun Or | Anti-infective pyrrolidine derivatives and analogs |
| US9447176B2 (en) | 2008-11-10 | 2016-09-20 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| SMT202200074T1 (it) | 2008-12-22 | 2022-03-21 | Chemocentryx Inc | Antagonisti di c5ar |
| US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| US20120252792A1 (en) | 2009-09-17 | 2012-10-04 | The Regents Of The University Of Michigan | Methods and compositions for modulating rho-mediated gene transcription |
| HRP20171176T1 (hr) | 2010-06-24 | 2017-10-06 | Chemocentryx, Inc. | C5ar antagonisti |
| AU2013277154A1 (en) | 2012-06-20 | 2014-12-18 | Jonathan E. Grob | Complement pathway modulators and uses thereof |
| EP3682879B1 (en) | 2014-09-29 | 2022-08-03 | ChemoCentryx, Inc. | Processes and intermediates in the preparation of c5ar antagonists |
| MX2022006069A (es) | 2016-01-14 | 2023-01-12 | Chemocentryx Inc | Metodo para tratar glomerulopatia c3. |
-
2011
- 2011-06-24 HR HRP20171176TT patent/HRP20171176T1/hr unknown
- 2011-06-24 SI SI201131229T patent/SI2585064T1/sl unknown
- 2011-06-24 WO PCT/US2011/041910 patent/WO2011163640A1/en not_active Ceased
- 2011-06-24 RS RS20170761A patent/RS56332B1/sr unknown
- 2011-06-24 HU HUE11799027A patent/HUE033644T2/en unknown
- 2011-06-24 US US13/806,339 patent/US9126939B2/en active Active
- 2011-06-24 JP JP2013516840A patent/JP2013529647A/ja not_active Withdrawn
- 2011-06-24 BR BR112012033075-6A patent/BR112012033075B1/pt active IP Right Grant
- 2011-06-24 EP EP11799027.5A patent/EP2585064B1/en active Active
- 2011-06-24 ES ES11799027.5T patent/ES2632975T3/es active Active
- 2011-06-24 PT PT117990275T patent/PT2585064T/pt unknown
- 2011-06-24 PL PL11799027T patent/PL2585064T3/pl unknown
- 2011-06-24 DK DK11799027.5T patent/DK2585064T3/en active
- 2011-06-24 CN CN201180039245.XA patent/CN103068385B/zh active Active
-
2015
- 2015-09-04 US US14/846,487 patent/US9573897B2/en active Active
-
2016
- 2016-03-17 JP JP2016053725A patent/JP6189989B2/ja active Active
-
2017
- 2017-01-06 US US15/400,820 patent/US20170114017A1/en not_active Abandoned
- 2017-08-03 JP JP2017150928A patent/JP6438086B2/ja active Active
- 2017-10-02 US US15/722,819 patent/US10035768B2/en active Active
-
2018
- 2018-06-27 US US16/020,139 patent/US20190062275A1/en not_active Abandoned
-
2020
- 2020-10-20 US US17/075,131 patent/US20210269398A1/en not_active Abandoned
-
2022
- 2022-09-26 US US17/935,434 patent/US20230102258A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171176T1 (hr) | C5ar antagonisti | |
| JP2018035160A5 (enExample) | ||
| JP2020128376A5 (enExample) | ||
| JP2014524442A5 (enExample) | ||
| JP2009502961A5 (enExample) | ||
| JP2019528276A5 (enExample) | ||
| JP2019527728A5 (enExample) | ||
| JP2018024682A5 (enExample) | ||
| CN110573500A (zh) | N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用 | |
| JP2019503167A5 (enExample) | ||
| NZ597596A (en) | Bicyclic aryl sphingosine 1-phosphate analogs | |
| JP2016512227A5 (enExample) | ||
| JP2016538257A5 (enExample) | ||
| JP2009542595A5 (enExample) | ||
| JP2018534286A5 (enExample) | ||
| JP2016510033A5 (enExample) | ||
| TW201024301A (en) | Amino pyrazole compound | |
| JP2010514807A5 (enExample) | ||
| JP2016529306A5 (enExample) | ||
| JP2021522262A5 (enExample) | ||
| JP2019525939A5 (enExample) | ||
| JP2016503010A5 (enExample) | ||
| JP2020518582A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2018507223A5 (enExample) |